Pd-Rx Pharmaceutical
PD-Rx Pharmaceuticals, Inc. engages in the repackaging and distribution of prepackaged pharmaceutical products for the healthcare industry in the United States. The company offers prepackaged medications, such as creams, ointments, ophthalmics, otics, liquids, and suspension products. It also provides packaging services. In addition, the company offers a dispensing platform, a manual dispensing s… Read more
Pd-Rx Pharmaceutical (PDRX) - Total Assets
Latest total assets as of June 2016: $13.25 Million USD
Based on the latest financial reports, Pd-Rx Pharmaceutical (PDRX) holds total assets worth $13.25 Million USD as of June 2016.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pd-Rx Pharmaceutical - Total Assets Trend (2013–2025)
This chart illustrates how Pd-Rx Pharmaceutical’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pd-Rx Pharmaceutical - Asset Composition Analysis
Current Asset Composition (June 2025)
Pd-Rx Pharmaceutical's total assets of $13.25 Million consist of 88.6% current assets and 11.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 51.5% |
| Accounts Receivable | $2.09 Million | 17.5% |
| Inventory | $1.79 Million | 15.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Pd-Rx Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pd-Rx Pharmaceutical's current assets represent 88.6% of total assets in 2025, a decrease from 90.6% in 2013.
- Cash Position: Cash and equivalents constituted 51.5% of total assets in 2025, up from 35.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 17.5% of total assets.
Pd-Rx Pharmaceutical Competitors by Total Assets
Key competitors of Pd-Rx Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
C.Q. Pharmaceutical Holding Co Ltd
SHE:000950
|
China | CN¥67.71 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥3.56 Billion |
|
Shandong Realcan Pharmaceutical Co Ltd
SHE:002589
|
China | CN¥15.33 Billion |
|
Hanmi Science
KO:008930
|
Korea | ₩1.45 Trillion |
|
BCM Alliance Bhd
KLSE:0187
|
Malaysia | RM147.86 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥7.59 Billion |
|
Excelsior Medical Co Ltd
TW:4104
|
Taiwan | NT$18.80 Billion |
|
CHC Healthcare Group
TW:4164
|
Taiwan | NT$14.83 Billion |
Pd-Rx Pharmaceutical - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Pd-Rx Pharmaceutical generates 1.53x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pd-Rx Pharmaceutical is currently not profitable relative to its asset base.
Pd-Rx Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.31 | 3.67 | 3.67 |
| Quick Ratio | 1.76 | 2.19 | 2.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $971.40K | $ 963.66K | $ 963.66K |
Pd-Rx Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Pd-Rx Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -6.9% |
| Total Assets | $11.98 Million |
| Market Capitalization | $26.02K USD |
Valuation Analysis
Below Book Valuation: The market values Pd-Rx Pharmaceutical's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pd-Rx Pharmaceutical's assets decreased by 6.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pd-Rx Pharmaceutical (2013–2025)
The table below shows the annual total assets of Pd-Rx Pharmaceutical from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $11.98 Million | -6.91% |
| 2024-06-30 | $12.87 Million | -0.64% |
| 2023-06-30 | $12.95 Million | -2.06% |
| 2022-06-30 | $13.22 Million | +21.15% |
| 2021-06-30 | $10.91 Million | +24.10% |
| 2020-06-30 | $8.79 Million | +1.24% |
| 2019-06-30 | $8.69 Million | -31.67% |
| 2018-06-30 | $12.71 Million | +0.62% |
| 2017-06-30 | $12.63 Million | -4.65% |
| 2016-06-30 | $13.25 Million | +10.70% |
| 2015-06-30 | $11.97 Million | +4.07% |
| 2014-06-30 | $11.50 Million | -2.63% |
| 2013-06-30 | $11.81 Million | -- |